Editor's key points
Little is known about the pharmacokinetics of the a2 agonist dexmedetomidine when it is applied intranasally.
Eight adults received 1 mg kg À1 dexmedetomidine on three separate occasions. Bioavailability was similar (~40%) for two methods of intranasal administration (drops or mucosal atomiser device). Degree and duration of sedation were similar for i.v. and intranasal administration.
Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist that acts on the locus ceruleus 1 to produce dosedependent sedation with no respiratory depression and only modest haemodynamic effects. 2, 3 The i.v. formulation is also efficacious when administered by the intranasal route in both children 4e8 and adults. 9, 10 Since this is not associated with any unpleasant sensation, there is increasing use for paediatric premedication and procedural sedation. 5, 11 There is one report on the bioavailability (65%) of intranasal dexmedetomidine in healthy volunteers, 12 performed with a special nasal pump and a highly concentrated veterinary formulation of dexmedetomidine (84 mg in 0.2 ml).
Since neither the nasal pump nor the veterinary formulation are available for human use, these data cannot be applied to clinical practice where intranasal dexmedetomidine is usually administered by drops with a 1-ml tuberculin syringe or by using a nasal mucosal atomisation device (MAD Nasal TM , Wolfe Tory Medical Inc., Salt Lake City, UT, USA). The aim of this study was to evaluate the pharmacokinetics and pharmacodynamics of dexmedetomidine with these two intranasal modes of administration in healthy volunteers and compare this with i.v. administration.
Methods
The study was approved by the Institutional Review Board of the University of Hong Kong (UW 12-373) and was registered with Hong Kong Clinical Trials Registry (HKCTR-1617). Written, informed consent was obtained from all participants before the study started. Healthy adults with ASA physical status class I were recruited. Exclusion criteria included BMI >30 kg m À2 , history of intolerance to the study drug or related compounds, concomitant drug therapy of any kind except paracetamol in the 14 days prior to the study, previous or present alcoholism, drug abuse, cigarette smoking, and abnormal ECG. All participants were requested to refrain from the use of any herbal medicine, any medications, and some natural products (including grapefruit products) for at least 14 days, and alcohol-and caffeine-containing products for at least 24 h. This was a three-period, crossover study. Eight participants, seven males and one female, aged from 29 to 42 years with BMI ranging from 19.1 to 28.5 kg m À2 were recruited and attended three study sessions. The study was double-blind to avoid bias during assessment of sedation status by both participants and observers. All participants received i.v. drug/ placebo and one mode of intranasal drug/placebo administration at the beginning of each study session. A crossover study design was used to reduce inter-individual variability (IIV). As there were three treatment periods for each participant and two possible routes of intranasal placebo whenever a participant received i.v. dexmedetomidine, the possible number of treatments with different assignment of intranasal placebo would be 12. However, whenever the intranasal route, be it placebo or active drug, were the same for the first two treatment periods, it would be possible for the participants and investigators to guess the route of active drug administration on the third study period. Therefore, eliminating those treatment and intranasal placebo combinations, the possible number of treatments was eight. All participants were randomly assigned to one of the eight possible treatment orders. Two independent anaesthesiologists who were not involved in data collection and drug administration were responsible for drug and placebo preparation during each study session. All syringes were labelled with the participants' name and identification number and were verified before drug administration during each study session. The study drugs were administered by investigators who were blinded to treatment allocation. The order of drug administration was randomly assigned once the participant was recruited into the study with a washout period of at least 7 days. In each of these sessions each participant received 1 mg kg À1 dexmedetomidine either i.v., intranasal by atomiser or intranasal by drops. I.V. dexmedetomidine was prepared in 50 ml 0.9% saline and was administered via a 20G i.v. cannula over 10 min with a programmable syringe pump. When intranasal dexmedetomidine was administered by atomisation or by drops, the parenteral formulation of undiluted dexmedetomidine (100 mg ml À1 ) at 1 mg kg À1 was used and drawn up in tuberculin (1 ml) syringes. When atomisation was used to deliver dexmedetomidine, the dead space of the atomiser was filled with dexmedetomidine before the drug was administered. An equal volume of drug was given via the two nostrils when the drug was administered intranasally. Atomisation was performed with the participant sitting up with a slight backward head tilt as this allows optimal spread and absorption of atomised solutions. 5 When the intranasal drug was administered by drops, participants were asked to lie flat so that the solution could be dripped into the nostrils. On the study day the participants were fasted from midnight until 3 h after the study drug administration. During this period water intake was allowed. Two 20G i.v. catheters, one on each upper limb, were inserted at the commencement of each session. One i.v. access was used for drug or placebo administration and the other for blood sampling. The study drug was administered after recording baseline pulse rate (PR), non-invasive systolic blood pressure (SBP), diastolic blood pressure (DBP), oxygen saturation (SpO 2 ), and sedation status. SpO 2 and pulse rate were monitored continuously for the first 3 h, while blood pressure and sedation status were recorded every 5 min. Participants were allowed to ambulate, eat, and drink after the third hour of investigation. After the third hour SBP, DBP, PR, SpO 2, and sedation status were monitored and recorded every hour. Sedation status was assessed by a blinded observer using the Ramsay sedation scale (Table S1 ) every 5 mins for the first 3 h, then every 30 min for the subsequent 5 h. Any changes in blood pressure or heart rate of greater than 20% in magnitude from baseline measurements were reported and managed by on-site anaesthesiologists. I.V. fluid administration and vasoactive drugs were readily available. Other discomfort or suspected side effects of study drugs were to be reported to investigators during and up to 48 h after the study period.
A venous cannula flushed with heparinised saline (10 IU ml
À1
) was used for blood sampling. Two-ml venous blood samples were collected immediately prior to administration of dexmedetomidine (baseline) and thereafter at 5, 7.5, 10, 15, 20, 30, and 45 mins and 1, 1.5, 2, 3, 4, 5, 6, and 8 h to determine concentrations of dexmedetomidine. Plasma was separated by centrifuging and was stored at À20 o C until batch analysis. A validated analytical method was developed with reference to a previously reported method 13 to analyse all the plasma samples. 200 ml plasma was extracted with ammonium acetate using diethyl ether and reconstituted by 50 ml of the mixture of 0.07% formic acid in water and acetonitrile (80:20). The ultraperformance liquid chromatography system, Waters ACQUITY UPLC system (Waters, Milford, MA, USA), equipped with ACQ-UITY UPLC BEH C18 Column, 130Å , 1.7 mm, 3 mm Â 50 mm, and a guard column ACQUITY UPLC BEH C18 VanGuard Pre-column, 130Å , 1.7 mm, 2.1 mm was used to perform chromatographic separation, and a tandem mass spectrometer (AB Sciex 6500 QTRAP) was used for detection. The mobile phase system was a gradient program consisting of formic acid in water (A) and acetonitrile (B) with a flow rate 0.5 ml min
. The gradient program was as follows: 0e0.5 min 90% A, 0.5e4.0 min gradually changed to 1% A, 4.5e5.0 min returned back to 90% A, 5.0e6.5 min maintained at 90% A. The method showed good linearity from 8.3 to 4230.7 pg ml À1 dexmedetomidine (r 2 ¼0.9999) with a lower limit of quantitation 8.3 pg ml
. The matrix effect introduced by six batches of blank plasma on the peak area of dexmedetomidine and internal standard was less than 20% at three quality control concentration levels (1692.3, 423.1, and 21.1 pg ml
). The intra-and inter-day precision, expressed as coefficient of variation, was less than 15%. The accuracy of the method was within the range of 85e115%. All plasma samples collected were analysed following the validation method, and finished within one month. The concentration of each plasma sample was calculated based on a calibration curve obtained in the method validation. 
Pharmacokinetic analysis
Compartmental PK model building began with i.v. data only, and a visible change in elimination rate seeming to coincide with heart rate led us to test the model derived by Dutta and colleagues 14 whereby clearance is driven by the well-stirred hepatic model [equation (1)]. Cardiac output was estimated as heart rate times stroke volume [equation (2)]. 15, 16 The stroke volume was fixed to 70 ml as it has been proven that the stroke volume of healthy adults would not be affected by dexmedetomidine if the plasma concentration is below 5 ng ml À1 .
2
Then hepatic blood flow was set to be 30% of cardiac output [equation (3)]. 17 Cl
Cardiac OutputðLitres=hÞ ¼ Heart Rateðbeats=hÞ
where Cl 0 represents intrinsic clearance, QH is hepatic blood flow. C B is concentration in blood, C P is concentration in plasma, and C B /C P represents the dexmedetomidine blood:plasma concentration ratio. f UB is fraction unbound in blood, calculated by fraction unbound in plasma f UP over C B /C P , the value of which were fixed to 0.0602 and 0.704, respectively, as reported previously.
14 Intranasal data was then incorporated to characterise absorption with the two modes of intranasal administration. A single first-order absorption with lag time, two parallel first order absorptions (rapid and slow) absorption with lag times, and the transit compartment model where the drug amount in the absorption compartment calculated by equation (4) , 18 were tested. Non-compartmental analysis was also performed using PKSolver.
where A(a) is the drug amount in the absorption compartment, t is time, F stands for bioavailability after intranasal administration, k tr is the transit rate constant from (nÀ1)th compartment to the nth compartment, n is the number of transit compartments, and ka is absorption rate constant.
Pharmacodynamic analysis
Ramsay sedation score was modelled as a time-varying ordered categorical variable, with the relationship between the probability of score at each time point and concentration being estimated with a sigmoidal E max model. The observed delay between circulating concentration and observed effect was modelled by using an effect compartment with first-order equilibration rate k eo . The possible relatedness of the score at a given time point with the preceding score was modelled using a Markov model (Supplementary Material 1) . 20 Probabilities for sedation score (SS) greater or equal to n (SS !n) given a preceding observation of sedation score equals to m (PSS¼m) was expressed by equation (5)
where log(n,m), the logits for SS!n given PSS¼m, was calculated by equation (6) logn;
where
where B k,m (k¼1,2,3,4) is the baseline values for sedation score k given a previous observation m. h is the between participant variability assumed to be normally distributed with mean 0 and variance u 2 . CE is the drug concentration in effect compartment.
Finally, probabilities for sedation score n given a previous observation of m can be calculated by equation (8) .
Pn; m ¼ PGEðn; mÞ À PGEðn þ 1; mÞ (8) A simulation study was performed to investigate the probability of each sedation level over time in each group and the onset time of each individual.
Onset of sedation was defined as the first time point when the Ramsay Sedation score was !5 and wake-up time defined as the first time point when the Ramsay Sedation score was 2 after onset. These values were chosen to reflect the level of sedation required for participants to undergo invasive procedures and the level of alertness before they could be safely discharged in a clinical setting. The observed onset time and duration of sedation were also analysed by log-rank and the Kaplan Meier method.
All PK/PD modelling was performed with NONMEM 7.3.0 (ICON Development Solutions, Hanover, MD, USA) and Pirana 2.9.2 (Pirana Software & Consulting BV, Amsterdam, the Netherlands), using first-order conditional estimation method with the interaction method for PK models and Laplacian method for PD models. The IIV, inter-occasional variability on Fig 2. (i) Basic goodness-of-fit plots for the final pharmacokinetic model and (ii) Visual predictive checks for dexmedetomidine pharmacokinetic profile after (a) intravenous, (b) intranasal by atomiser, (c) intranasal by drops administration. Observed data is shown as circles, the median of observed data as gray solid line, the 50th, 5th, and 95th percentile of simulated data as black solid line and dashlines, respectively. structural parameters and residual error were evaluated. The PD model was constructed using the sequential approach where individual PK parameters were fixed to the post hoc values obtained from the final PK model. Different models were evaluated by Goodness-of-fit and statistical significance in objective-function-value (OFV) change. R 3.2.2 was used for graphical plots. 21 
Results
All eight participants completed three study sessions. Analysis of variance for a 3Â3 crossover trial revealed no sequence, period, or carry over effects on AUC (area under the curve) for dexmedetomidine timeeplasma concentration, Ramsay sedation scores, blood pressure, heart rate, and SpO 2 . Observed plasma concentration, Ramsay sedation score, and change in heart rate and SBP are presented in Fig. 1 .
A two-compartment model, with well-stirred model for clearance and transit compartment model for absorption, best described dexmedetomidine PK. After introducing the wellstirred model to describe the relationship between clearanceehepatic blood flowecardiac outputeheart rate, a significant improvement in modelling was observed (ÀDOFV: 10. , which were similar to previous reported values. 13, 23, 24 Derived from equations (1)e(3), clearance decreased up to around 40% as dexmedetomidine plasma concentration increased. The heart rate reached its lowest value at around 2 h after dosing, and gradually rebounded to the baseline afterwards as plasma concentration decreased [ Fig. 1 (c) ]. A similar trend was observed in the predicted clearance and hepatic blood flow (figure not shown). The transit model improved the goodness-of-fit and decreased OFV, compared with first-order absorption with lag time model (ÀDOFV: 55.3, P<0.05) and two parallel absorption models (ÀDOFV: 18.2, P<0.05). The mean transit time (MTT) were 10.74 min and 10.02 min, and the absorption rate constant (k a ) was 0.855h À1 and 0.722h À1 for intranasal by atomiser and intranasal by drops, respectively. The bioavailability was 40.6% (IIV 35.1%) and 40.7% (IIV 31.9%) for intranasal atomisation and by drops, respectively. Parameter estimates for the final pharmacokinetic model are given in Table 1 . Goodnessof-plots and visual predictive checks are presented in Fig. 2 . The individual plot of observed and predicted plasma concentration over time is presented in Fig. S1 . As there was no sedation score 1 (anxious or restless or both) recorded in this study, the functional minimum score was 2 (cooperative, orientated, and tranquil). Application of the hypothetical effect compartment decreased the OFV significantly (ÀDOFV: 233.3, P<0.05) compared to a model without effect compartment. Introducing a baseline E 0 into the E max model did not improve model fit (ÀDOFV: 0). Thus we used the sigmoidal E max model to describe impact of concentration in the effect compartment on probability of sedation score. Finally, the PD model was further improved by introducing the Markov elements (ÀDOFV: 818.5, P<0.05), with better visual predictive check results. The parameter estimates of the final pharmacodynamic model are shown in Table 3 . The value of k eo was 12.6 h À1 , corresponding to a rapid effect delay of 3.3 min. The administration route showed no significant impact on the k eo , as no significant inter-occasional variability was found. EC50 was 903 pg ml À1 with IIV of 36.6%.
The categorical visual predictive check plot (Fig. S2 in supplementary information) shows that the probability of each sedation score over time can be well predicted by the PD model. The simulated probability of being sedated (sedation score !5) over time after administration of 1mg kg À1 dexmedetomidine by i.v. or intranasal routes is shown in Fig. 3 . A schematic diagram of the final PK and PD model is shown in À1.51 (19%) B 3,pre¼2 À0.838 (40%) B 4,pre¼2 À0.758 (58%) E max,pre¼2
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E max : maximum drug effect on the logit scale. EC50: concentration in effect compartment causing half E max.
g: steepness coefficient of concentration effect k eo : first-order distribution constant of drug into and out of effect compartment. B k,pre¼m : baseline fixed-effects parameters of the logit transformation of probabilities given a previous observation of sedation score equals to m.
As there was no transition from sedation score 6 to 2, B 1,pre¼6 was fixed to 20. Table S3 . Log likelihood profiles of the PK and PD models are presented in Supplementary Material 2.
Statistical analysis of the raw data showed that the median time to onset of sedation was 15 (95% CI 15e20), 47.5 (95% CI 25e135) and 60 (95% CI 30e75) min for i.v., intranasal by atomiser and intranasal by drops, respectively ( Table 2 ). The i.v. route has a significantly faster onset when compared to atomiser and drops (P<0.001 and P<0.001, respectively) while there was no difference in sedation onset between the atomiser and drops. The median duration of sedation was 202.5 (95% CI 105e225), 147.5 (95% CI 65e220) and 170 (95% CI 155e180) min for i.v., intranasal by atomiser and intranasal by drops, respectively (Table 2 ). There was no difference in the median duration of sedation (P¼0.88). The model predicted individual onset time was presented in Fig. S4 .
Both intranasal and i.v. dexmedetomidine were well tolerated with no reported irritation or pain associated with administration of the drug. There were decreases in blood pressure and heart rate after administration in all three treatment groups. However, they were not associated with any subjective symptoms and did not require intervention or treatment.
Discussion
We have shown that bioavailability does not differ whenever intranasal dexmedetomidine is given by simple drops or by an atomisation device, and there is no significant difference in their pharmacokinetic or pharmacodynamic profiles. A recent prospective, randomised, controlled trial comparing the two modes of intranasal dexmedetomidine in children undergoing transthoracic ECG also showed similar clinical effects with these two modes of administration. 25 The dose used in this adult study was 1 mg kg À1 whereas the dose used in the paediatric clinical trial was 3 mg kg
À1
. In both studies the undiluted i.v. formulation was used; hence the volume of drug administration correlates with the drug dose. Compared to children, adults should have a larger surface area for intranasal drug absorption, yet atomisation did not result in improved bioavailability. Atomisation also does not improve clinical effectiveness when the dose is relatively larger in children. To date we have no information on the bioavailability when using higher doses of intranasal dexmedetomidine in adults and children.
In this study the bioavailability of both intranasal routes was lower than that estimated by Iirola and colleagues. 12 This could be secondary to the difference in formulation as the veterinary formulation was much more concentrated, which should result in better absorption. In order to produce a fine mist with the atomisation device one needs to apply brisk high pressure to the atomiser. The drug deposition pattern during intranasal administration with a nasal cast silicone model has been studied, 26 and it has been suggested that the administration angle is a critical factor in optimising drug deposition, with an administration angle >60 o and slight head tilt best. Whether this will translate to the clinical effect would be an interesting subject of research. However, it would be difficult to control the angle of administration in the clinical setting, especially in children. The population mean bioavailability is 40.7% (95% CI 36.5%e53.2%) and 40.6% (95% CI 34.7%e54.4%) for intranasal by drops and intranasal by atomiser. The corresponding geometric mean of bioavailability obtained in non-compartmental analysis is 51.2% (95% CI 31.7%e88.7%) and 48.2% (95% CI 37.4%e69.5%), respectively. The discrepancy might be as a result of high between-participant variability and small number of participants. Also, noncompartmental analysis, without considering non-linear pharmacokinetics or assay error, might introduce bias in AUC and bioavailability calculation.
27,28
The plasma dexmedetomidine concentration associated with a loading dose and constant infusion of dexmedetomidine has been studied in patients in critical care. 29 With a loading dose of 0.5e1 mg kg À1 over 10 min and an infusion rate of
, the resulting constant plasma dexmedetomidine concentrations were generally higher than 1 ng ml À1 and these concentrations were correlated with light to moderate sedation. We have shown that 1 mg kg À1 of intranasal dexmedetomidine results in a median peak plasma concentration of 0.28 and 0.25 ng ml À1 for atomiser and drops, respectively (Table S2) ; these levels are lower than those resulting from constant i.v. infusion. Future pharmacokinetic studies would be useful to determine whether increasing the dose of intranasal dexmedetomidine will increase systemic absorption to an extent that mimics the concentration resulting from i.v. infusion. The arteriovenous concentration difference and its effect on pharmacokinetics and pharmacodynamics of dexmedetomidine is unclear. One study using arterial concentration for PK modelling found similar central clearance yet different distribution volume compared with those using venous concentration data. 30 The suggested physiological covariates include body weight, 30 age, 29 height, 31 albumin concentration, 23 cardiac output, 14 and co-existent pathology. 22 No significant covariate was found in our study, which was probably due to the narrow range of these covariates and small sample size. Future studies could explore possible covariates that are correlated with the intrinsic clearance.
Intranasal dexmedetomidine is associated with a slower and more gradual onset than i.v. administration. Although i.v. administration results in much higher peak plasma concentrations and earlier onset, the depth of sedation is similar once it occurs. A more gradual onset may actually be desirable in avoiding the a-1 agonist effects seen with rapid i.v. administration (hypertension and bradycardia). While there is no significant difference in the parameter estimates, the probability of being sedated after intranasal by atomiser administration is higher than that after intranasal by drop administration. The clinical relevance can be further investigated.
Conclusion
The bioavailability of intranasal dexmedetomidine by atomiser and by drops is approximately 40% in healthy adult volunteers with an inter-individual variability of around 30%. The pharmacokinetic and pharmacodynamic profiles of the two modes of administration are similar and both are equally effective in inducing adequate sedation.
